SG11202111109UA - Biparatopic fr-alpha antibodies and immunoconjugates - Google Patents
Biparatopic fr-alpha antibodies and immunoconjugatesInfo
- Publication number
- SG11202111109UA SG11202111109UA SG11202111109UA SG11202111109UA SG11202111109UA SG 11202111109U A SG11202111109U A SG 11202111109UA SG 11202111109U A SG11202111109U A SG 11202111109UA SG 11202111109U A SG11202111109U A SG 11202111109UA SG 11202111109U A SG11202111109U A SG 11202111109UA
- Authority
- SG
- Singapore
- Prior art keywords
- biparatopic
- immunoconjugates
- alpha antibodies
- antibodies
- alpha
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962840297P | 2019-04-29 | 2019-04-29 | |
US201962879864P | 2019-07-29 | 2019-07-29 | |
PCT/US2020/030245 WO2020223221A1 (en) | 2019-04-29 | 2020-04-28 | Biparatopic fr-alpha antibodies and immunoconjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111109UA true SG11202111109UA (en) | 2021-11-29 |
Family
ID=73028723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111109UA SG11202111109UA (en) | 2019-04-29 | 2020-04-28 | Biparatopic fr-alpha antibodies and immunoconjugates |
Country Status (12)
Country | Link |
---|---|
US (2) | US11396543B2 (en) |
EP (1) | EP3962935A4 (en) |
JP (1) | JP2022530524A (en) |
KR (1) | KR20220004687A (en) |
CN (1) | CN114222756A (en) |
AU (1) | AU2020265568A1 (en) |
CA (1) | CA3138272A1 (en) |
IL (1) | IL287451A (en) |
MA (1) | MA55818A (en) |
SG (1) | SG11202111109UA (en) |
TW (1) | TW202100557A (en) |
WO (1) | WO2020223221A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
TW202100557A (en) | 2019-04-29 | 2021-01-01 | 美商免疫遺傳股份有限公司 | Biparatopic fr-alpha antibodies and immunoconjugates |
TW202306995A (en) * | 2021-06-04 | 2023-02-16 | 美商免疫遺傳股份有限公司 | Treatment of cancer in patients with soluble fr-alpha |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2024026340A1 (en) * | 2022-07-26 | 2024-02-01 | Shattuck Labs, Inc. | Combination therapy for treatment of ovarian cancer |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4805848B2 (en) | 2004-02-12 | 2011-11-02 | モルフォテック、インク. | Monoclonal antibodies that specifically block the biological activity of tumor antigens |
EP1879922A2 (en) | 2005-04-22 | 2008-01-23 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
DK2538976T3 (en) | 2010-02-24 | 2017-02-27 | Immunogen Inc | IMMUNCONJUGATES AGAINST FOLATRECEPTOR-1 AND APPLICATIONS THEREOF |
ES2627061T3 (en) | 2010-11-05 | 2017-07-26 | Morphotek, Inc. | Folate alpha receptor as diagnosis and prognosis for marker folate receptor of alpha-expressing cancers |
EA028805B1 (en) | 2011-04-01 | 2018-01-31 | Иммьюноджен, Инк. | Methods for increasing efficacy of folr1 cancer therapy |
US20120282282A1 (en) | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
RS60217B1 (en) | 2012-08-31 | 2020-06-30 | Immunogen Inc | Diagnostic assays and kits for detection of folate receptor 1 |
RU2015149285A (en) | 2013-05-14 | 2017-06-19 | Иммьюноджен Инк. | IMMUNOCONJUGATE DOSAGE SCHEMES ANTI-FOLR1 |
AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
KR20220136468A (en) | 2013-10-08 | 2022-10-07 | 이뮤노젠 아이엔씨 | Anti-folr1 immunoconjugate dosing regimens |
US20170247449A1 (en) | 2014-06-06 | 2017-08-31 | Kyowa Hakko Kirin Co., Ltd | Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism |
EP3188761A4 (en) | 2014-09-02 | 2018-04-18 | ImmunoGen, Inc. | Methods for formulating antibody drug conjugate compositions |
CN108601828B (en) * | 2015-09-17 | 2023-04-28 | 伊缪诺金公司 | Therapeutic combinations comprising anti-FOLR 1 immunoconjugates |
CN116785450A (en) * | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof |
GB201707864D0 (en) | 2017-05-16 | 2017-06-28 | Inst Of Cancer Research: Royal Cancer Hospital | Platinum-reistant cancer treatment |
US20200284810A1 (en) | 2017-09-05 | 2020-09-10 | Immunogen, Inc. | Methods for detection of folate receptor 1 in a patient sample |
CA3073414A1 (en) | 2017-09-22 | 2019-03-28 | Immunogen, Inc. | Separation of triple-light chain antibodies using cation exchange chromatography |
WO2019140141A1 (en) | 2018-01-12 | 2019-07-18 | Immunogen, Inc. | Methods for antibody drug conjugation, purification, and formulation |
TW202100557A (en) * | 2019-04-29 | 2021-01-01 | 美商免疫遺傳股份有限公司 | Biparatopic fr-alpha antibodies and immunoconjugates |
TW202306995A (en) * | 2021-06-04 | 2023-02-16 | 美商免疫遺傳股份有限公司 | Treatment of cancer in patients with soluble fr-alpha |
-
2020
- 2020-04-28 TW TW109114175A patent/TW202100557A/en unknown
- 2020-04-28 MA MA055818A patent/MA55818A/en unknown
- 2020-04-28 CA CA3138272A patent/CA3138272A1/en active Pending
- 2020-04-28 CN CN202080037442.7A patent/CN114222756A/en active Pending
- 2020-04-28 SG SG11202111109UA patent/SG11202111109UA/en unknown
- 2020-04-28 JP JP2021564298A patent/JP2022530524A/en active Pending
- 2020-04-28 KR KR1020217037919A patent/KR20220004687A/en unknown
- 2020-04-28 WO PCT/US2020/030245 patent/WO2020223221A1/en unknown
- 2020-04-28 AU AU2020265568A patent/AU2020265568A1/en active Pending
- 2020-04-28 US US16/860,822 patent/US11396543B2/en active Active
- 2020-04-28 EP EP20798751.2A patent/EP3962935A4/en active Pending
-
2021
- 2021-10-20 IL IL287451A patent/IL287451A/en unknown
-
2022
- 2022-06-10 US US17/838,016 patent/US11834498B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2020223221A1 (en) | 2020-11-05 |
IL287451A (en) | 2021-12-01 |
CA3138272A1 (en) | 2020-11-05 |
US11834498B2 (en) | 2023-12-05 |
TW202100557A (en) | 2021-01-01 |
US20230085779A1 (en) | 2023-03-23 |
US20200362029A1 (en) | 2020-11-19 |
EP3962935A1 (en) | 2022-03-09 |
KR20220004687A (en) | 2022-01-11 |
JP2022530524A (en) | 2022-06-29 |
AU2020265568A1 (en) | 2021-11-04 |
EP3962935A4 (en) | 2023-05-31 |
US11396543B2 (en) | 2022-07-26 |
MA55818A (en) | 2022-03-16 |
CN114222756A (en) | 2022-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275737A (en) | Antibodies and variants thereof against tigit | |
IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
IL278846A (en) | Anti-cd3 antibodies and uses thereof | |
IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
EP3604338A4 (en) | Anti-ox40 antibody and use thereof | |
IL287451A (en) | Biparatopic fr-alpha antibodies and immunoconjugates | |
SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
IL289585A (en) | Dll3-targeting antibodies and uses thereof | |
IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
EP3625262A4 (en) | Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations | |
IL288998A (en) | Anti-mesothelin antibodies and immunoconjugates thereof | |
IL287690A (en) | Anti-hvem antibodies and use thereof | |
SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
IL282707A (en) | Anti-tim-3 antibodies and their use | |
IL282708A (en) | Anti-tim-3 antibodies and their use | |
IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
IL289656A (en) | Anti-tigit antibodies and application thereof | |
IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
EP4032904A4 (en) | Anti-alpha-hemolysin antibody and use thereof | |
IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
IL276548A (en) | Bcma-binding antibodies and uses thereof |